AMYVID

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Ireland, Japan, Lithuania, Poland.

Active ingredients

The drug AMYVID contains one active pharmaceutical ingredient (API):

1	Florbetapir ¹⁸F UNII 6W15Z5R0RU - FLORBETAPIR F-18
	Florbetapir ¹⁸F binds to β-amyloid plaques and the ¹⁸F isotope produces a positron signal that is detected by a PET scanner. Florbetapir ¹⁸F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.
	Read more about Florbetapir ¹⁸F

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AMYVID Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09AX05		V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AX Other central nervous system diagnostic radiopharmaceuticals
Discover more medicines within V09AX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1618657, 1618668, 1618679, 1618680
JP	医薬品医療機器総合機構	43004A2A1029
LT	Valstybinė vaistų kontrolės tarnyba	1069110, 1069111, 1069112, 1069113
PL	Rejestru Produktów Leczniczych	100305831, 100305848
US	FDA, National Drug Code	0002-1200